3SBio enters licensing deal for antibody-drug conjugate ALT-P7
Posted: 12 October 2015 | Victoria White
Preclinical proof-of-concept has demonstrated superiority of ALT-P7 over current drugs in murine models of HER2-positive breast cancer…
3SBio has entered into an exclusive licensing deal with Alteogen for the development, manufacturing and marketing of ALT-P7, a novel antibody-drug conjugate targeting HER2 pathway for cancer in the territory of Mainland China, Hong Kong and Macau.
Approximately 20% of breast cancers and 15% of gastric cancers are characterised by amplification of the human epidermal growth factor receptor 2 (HER2) gene and over-expression of HER2. 3SBio has said that ALT-P7, developed based on Alteogen’s proprietary NexMab antibody-drug conjugate technology, is expected to be more efficacious and stable compared with first generation antibody-drug conjugate products. Preclinical proof-of-concept, including in vitro binding assays and in vivo efficacy in animal models, has demonstrated superiority of ALT-P7 over current drugs in murine models of HER2-positive breast cancer.
ALT-P7 is a novel antibody-drug conjugate with “great potential”
“This is our first collaboration with Alteogen,” Dr Jing Lou, Chairman and CEO of 3SBio commented, “We are impressed by Alteogen’s NexMab antibody-drug conjugate technology and look forward to working with them as we seek regulatory approvals to move ALT-P7 into clinical trials in China. Novel mAb candidates, including antibody-drug conjugates and bispecific antibodies, shed light on the treatment for refractory or metastatic cancers, such as breast and gastric cancers, which is consistent with 3SBio’s core therapeutic areas of oncology and nephrology.”
“We are very pleased to start our partnership with 3SBio,” Dr Soon Jae Park, CEO of Alteogen commented, “3SBio is a well-established industry leader with long-term vision in the innovative biological field in China, which makes them an ideal partner for strategic collaborations in the long term. ALT-P7 is a novel antibody-drug conjugate with great potential to treat refractory tumours. We are looking forward to working with them to develop this drug in China, so that tens of thousands of patients suffering for cancers can benefit from this drug candidate.”